Editas Medicine Announces Executive and Board Changes
Ticker: EDIT · Form: 8-K · Filed: Jun 27, 2024 · CIK: 1650664
Sentiment: neutral
Topics: executive-change, board-appointment, personnel
TL;DR
Editas Medicine swaps CMO, adds new board member.
AI Summary
Editas Medicine, Inc. announced on June 27, 2024, the departure of its Chief Medical Officer, Dr. Michael Cheng. The company also appointed Dr. Sarah Boyce as the new Chief Medical Officer and elected Dr. David R. Liu to its Board of Directors. These changes are effective immediately.
Why It Matters
These executive and board changes could signal a shift in the company's strategic direction or leadership focus in the gene-editing space.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Editas Medicine, Inc. (company) — Registrant
- Dr. Michael Cheng (person) — Departing Chief Medical Officer
- Dr. Sarah Boyce (person) — Appointed Chief Medical Officer
- Dr. David R. Liu (person) — Elected to Board of Directors
- June 27, 2024 (date) — Effective date of changes
FAQ
Who has departed from Editas Medicine?
Dr. Michael Cheng, the Chief Medical Officer, has departed from Editas Medicine.
Who has been appointed as the new Chief Medical Officer?
Dr. Sarah Boyce has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Dr. David R. Liu has been elected to the Board of Directors.
When are these changes effective?
The changes are effective as of June 27, 2024.
What is the company's principal executive office address?
The principal executive office address is 11 Hurley Street, Cambridge, Massachusetts 02141.
Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 12 · Accepted 2024-06-27 17:02:58
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share EDIT The Nasdaq Sto
Filing Documents
- edit-20240627.htm (8-K) — 23KB
- 0001650664-24-000081.txt ( ) — 143KB
- edit-20240627.xsd (EX-101.SCH) — 2KB
- edit-20240627_lab.xml (EX-101.LAB) — 21KB
- edit-20240627_pre.xml (EX-101.PRE) — 12KB
- edit-20240627_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDITAS MEDICINE, INC. Date: June 27, 2024 By: /s/ Gilmore O'Neill Gilmore O'Neill President & Chief Executive Officer